Analysis of PD-1/PD-L1 variations in lung cancer and association with immunotherapeutic efficacy and prognosis: A nonrandomized controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Analysis of PD-1/PD-L1 variations in lung cancer and association with immunotherapeutic efficacy and prognosis: A nonrandomized controlled trial

Published:2024-01 Issue: Volume:79 Page:100395
ISSN:1807-5932
Container-title:Clinics
language:en
Short-container-title:Clinics

Author:

Ma Jun^ORCID,Song JianRui^ORCID,Han LiNa^ORCID,Zhou Wen^ORCID,Meng LiFeng^ORCID,Li JianHui^ORCID,Bai XiaoMing^ORCID

Publisher

Elsevier BV

Reference27 articles.

1. Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer;Cho;Int J Radiat Oncol Biol Phys,2019

2. Immunotherapy for small cell lung cancer: mechanisms of resistance;Hamilton;Expert Opin Biol Ther,2019

3. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis;Yvorel;PLoS One,2017

4. Fucosylated α1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer;Yokobori;Sci Rep,2019

5. Heuzé-Vourc'h N. Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines?;Guillon;Crit Care,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3